TherapeuticsMD, Inc. Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
TherapeuticsMD, Inc. (TXMD) had Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net of $12.30 million as of 2020-12-31, per its 10-K filed 2021-03-04.
Discontinued › Notes › Debt › Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet · last filed 2021-03-04
- 2020-12-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $12.30M.
- 2020-09-30: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $12.95M.
- 2020-06-30: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $6.20M.
- 2020-03-31: Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net $6.57M.
| Period end | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net |
|---|---|
| 2020-12-31 | $12.30M 10-K · filed 2021-03-04 |
| 2020-09-30 | $12.95M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $6.20M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $6.57M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $5.37M 10-K · filed 2021-03-04 |
| 2019-09-30 | $5.64M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $5.90M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $1.50M 10-Q · filed 2019-05-08 |
| 2018-12-31 | $1.62M 10-K · filed 2020-02-24 |
| 2018-09-30 | $1.74M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $1.86M 10-Q · filed 2018-07-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |